LRP1 and Alzheimer disease: In a mouse model of Alzheimer’s disease, induced by intracerebroventricular (icv) injection of Aβ1-42, daily administration of PRE-084 (1 mg/kg) for 21 days attenuated the amyloid-induced BBB disruption by inhibiting amyloid deposition and increasing expression of LRP-1 [29].